Next, because the antiangiogenic therapy is a critical part of the current targeted therapy against advanced cancers and JX also has antiangiogenic effects, we examined the possible cooperation between these two agents for treating PC of colon cancer.43 44 We treated MC38 peritoneal tumor-bearing mice with anti-VEGFR2 (DC101) or anti-PD-1 (figure 7D–F). This evidence concerns the gene KDR and pachyonychia congenita.